Lazid Tablets

Each Lazid Tablets contains: Lamivudine 150 mg + Zidovudine 300 mg

Indications :
Treatment of HIV infection in combination with NNRTIs or PIs

Contraindications :
Hypersensitivity to any of the components of the formulation

Adverse Reactions :
Headache, Malaise and fatigue, nausea/vomiting, diarrhea, anorexia, abdominal pain, abdominal cramps and dyspepsia. Lactic acidosis and severe hepatomegaly with steatosis and recurrent hepatitis following discontinuation of therapy have also been reported Hematological adverse events include neutropenia, anemia, and thrombocytopenia. Chills or fever were reported in 10% of patients treated with combined lamivudine/zidovudine therapy.

Precautions
Should be used with caution in patients with hepatic disease or in those with known risk factors for liver disease, patients with impaired renal function, including renal failure and patients who have bone marrow suppression. Treatment should be discontinued in any patient who develops lactic acidosis or pronounced hepatotoxicity which may include hepatomegaly and steatosis. Patients should be closely monitored for several months after stopping lamivudine+zidovudine therapy for hepatitis B. Frequent blood counts are strongly recommended in patients with advanced HIV disease who are treated with combination. Myopathy and myositis have been associated with prolonged use of zidovudine and therefore may occur with therapy with the combination